Values as of: 2024-10-30
COMMON STOCK | Biotechnology |
Last Closing
USD 16.96Change
+0.25 (+1.50)%Market Cap
USD 3.95BVolume
2.33MAnalyst Target
USD 9.83Verdict
Verdict
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey. Address: 465 State Route 17, Ramsey, NJ, United States, 07446
Company Website : https://www.admabiologics.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| VRTX | Vertex Pharmaceuticals Inc |
+4.72 (+1.00%) |
USD 121.32B |
| REGN | Regeneron Pharmaceuticals Inc |
-4.54 (-0.49%) |
USD 103.77B |
| ALNY | Alnylam Pharmaceuticals Inc |
-3.20 (-1.12%) |
USD 36.83B |
| ARGX | argenx NV ADR |
-1.17 (-0.21%) |
USD 33.21B |
| BGNE | BeiGene Ltd |
-10.54 (-4.87%) |
USD 24.57B |
| MRNA | Moderna Inc |
-0.50 (-0.91%) |
USD 20.52B |
| RPRX | Royalty Pharma Plc |
+0.04 (+0.15%) |
USD 16.47B |
| UTHR | United Therapeutics Corporatio.. |
+8.60 (+2.44%) |
USD 15.69B |
| SMMT | Summit Therapeutics PLC |
-3.18 (-14.57%) |
USD 15.13B |
| PCVX | Vaxcyte Inc |
+0.55 (+0.52%) |
USD 13.95B |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| BBP | Virtus LifeSci Biotech Pr.. | 2.21 % | 0.79 % |
-0.56 (0.27%) |
USD 0.02B |
| DWAS | Invesco DWA SmallCap Mome.. | 1.23 % | 0.60 % |
+0.23 (+0.27%) |
USD 0.99B |
| ISMD | Inspire Small/Mid Cap Imp.. | 0.00 % | 0.62 % |
+0.10 (+0.27%) |
USD 0.19B |
| Market Performance vs. Industry/Classification (Biotechnology) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 275.22% | 72% | C | 86% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 275.22% | 72% | C | 86% | B+ | ||
| Trailing 12 Months | |||||||
| Capital Gain | 381.82% | 72% | C | 87% | B+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 381.82% | 72% | C | 87% | B+ | ||
| Trailing 5 Years | |||||||
| Capital Gain | 241.25% | 70% | C- | 85% | B | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 241.25% | 70% | C- | 85% | B | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 56.26% | 80% | B- | 89% | A- | ||
| Dividend Return | 56.26% | 80% | B- | 89% | A- | ||
| Total Return | N/A | N/A | N/A | N/A | N/A | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 108.36% | 36% | F | 19% | F | ||
| Risk Adjusted Return | 51.92% | 95% | A | 79% | B- | ||
| Market Capitalization | 3.95B | 94% | A | 87% | B+ | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
